Biotechnology company Moderna Inc (Nasdaq:MRNA) reported on Thursday that the US government has purchased an additional 100m doses of its COVID-19 Vaccine to bring its confirmed order commitment to 300m doses.

The company is on track to deliver the first 100m doses in the Q1 2021 and the second order of 100m doses in the Q2 2021. It is working with its domestic manufacturing partners and the US FDA to continue to explore ways to accelerate delivery of the vaccine. It will continue to leverage the US -based manufacturing infrastructure to supply the COVID-19 Vaccine to the US government.

According to the company, it has supplied 41m released doses of the vaccine to the US government to date. More than 22m Americans have received the Moderna COVID-19 Vaccine in the US, according to the US Centers for Disease Control and Prevention.

This COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and the National Institute of Allergy and Infectious Disease's (NIAID) Vaccine Research Centre.